Inhibrx Biosciences Slips 1% Despite 11-of-25 Phase 2 Cancer Responses

4 articles · Updated · Barron's · May 11

Inhibrx Biosciences fell 1% to $133 on Monday even after reporting positive preliminary Phase 2 data for INBRX-106 in head and neck cancer; the stock had been up 10% premarket.
11 of 25 patients given INBRX-106 plus pembrolizumab achieved a confirmed objective response, versus 6 of 28 patients receiving pembrolizumab alone.
The trial targets metastatic or unresectable recurrent head and neck squamous cell carcinoma, and CEO Mark Lappe said the company was encouraged by the early clinical results.
Phase 3 is scheduled to start in the third quarter, with progression-free survival data expected in the fourth quarter of 2026.
Shares are still up more than 1,000% over the past 12 months, driven largely by positive October data for Inhibrx's other investigational cancer drug, INBRX-109.

With positive cancer drug results, why did Inhibrx's stock fall after a 1000% run-up?

Could this new drug be Merck’s multi-billion dollar answer to its looming Keytruda patent cliff?

How could a new 'gas pedal' for T-cells fundamentally shift the ceiling of cancer immunotherapy?